Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.

@article{Brunet2004TreatmentOP,
  title={Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.},
  author={Salut Brunet and Jordi Esteve and Joan Berlanga and Josep-Maria Ribera and Javier Bueno and Josep Mar{\'i}a Montserrat Mart{\'i} and Joan Bargay and Ram{\'o}n Camats I Guardia and A Chitaeva Julia and Albert Gra{\~n}ena and Emili Montserrat and Jorge Sierra},
  journal={Haematologica},
  year={2004},
  volume={89 8},
  pages={
          940-9
        }
}
BACKGROUND AND OBJECTIVES To evaluate a regimen of induction and consolidation chemotherapy, followed by a post-remission therapy which depended on age and cytogenetics, in patients with primary acute myeloid leukemia. DESIGN AND METHODS Two hundred patients up to 60 years old received idarubicin, standard dose cytarabine and etoposide as induction chemotherapy and one consolidation course including intermediate dose cytarabine and mitoxantrone. Subsequently, patients with favorable… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.

  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND